26 February 2019 in Nature Biotechnology
16 September 2015 in Nature
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
25 March 2019 in Nature Medicine
12 July 2016 in Nature Biotechnology
To the Editor: Recent progress in genome editing technologies, in particular the CRISPR-Cas9 nuclease system, has provided new opportunities to investigate the biological functions of genomic sequences by targeted mutagenesis1, 2, 3, 4. Double-strand breaks (DSBs) arising from site-specific Cas9 cleavage can be resolved by non-homologous end joining (NHEJ) or homology-directed… Download references
16 March 2020 in Nature Medicine
6 November 2019 in Blood Advances
TMThiyagaraj Mayuranathan
+21
Key Points: Cas9 editing of the γ-globin gene promoters in hematopoietic stem cells (HSCs) increases red cell HbF by ≤40%. No deleterious effects on hematopoiesis or off-target mutations were detected 16 weeks after xenotransplantation of edited HSCs.